Adam Crystal - 30 Jan 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Medical Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 30 Jan 2023
Net transactions value: -$10,122
Form type: 4
Filing time: 01 Feb 2023, 15:11:13 UTC
Previous filing: 14 Jun 2022
Next filing: 02 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Options Exercise		+3,750	+21%		21,398	30 Jan 2023	Direct	F1
transaction	CCCC	Common Stock	Tax liability	$10,122	-1,301	-6.1%	$7.78	20,097	30 Jan 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Performance Restricted Stock Units	Options Exercise	$0	-3,750	-17%	$0.000000	18,750	30 Jan 2023	Common Stock	3,750		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.